Amgen (HKSE:04332) Total Liabilities: HK$657,983 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:04332 Amgen Inc HKSE:04332
79 GF Score
Price HK$1,761.00
GF Value HK$1,463.66
! 8 Warning Signs
View Full Analysis

What is Amgen Total Liabilities?

Amgen HKSE:04332 79 Total Liabilities is HK$657,983 Mil as of Jun. 2026. GuruFocus rates HKSE:04332 with a GF Score™ of 79/100 and a GF Value™ of HK$1,463.66. The stock has 8 warning signs investors should review.

Amgen's Total Liabilities for the quarter that ended in Jun. 2026 was HK$657,983 Mil.

Amgen's quarterly Total Liabilities increased from Dec. 2025 (HK$637,465.38 Mil) to Mar. 2026 (HK$652,082.02 Mil) and increased from Mar. 2026 (HK$652,082.02 Mil) to Jun. 2026 (HK$657,982.75 Mil).

Amgen's annual Total Liabilities declined from Dec. 2023 (HK$710,082.64 Mil) to Dec. 2024 (HK$668,217.01 Mil) and declined from Dec. 2024 (HK$668,217.01 Mil) to Dec. 2025 (HK$637,465.38 Mil).

Amgen Total Liabilities Historical Data

* Premium members only.

The historical data trend for Amgen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Total Liabilities Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 424,772.54 478,490.68 710,082.64 668,217.01 637,465.38

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 631,568.99 626,839.61 637,465.38 652,082.02 657,982.75
HKSE:04332
79GF Score
Amgen Inc HKSE:04332
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amgen's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=198324.811+(389078.904+18502.742
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+10628.573+0+20930.352)
=637,465

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=704831.549-67366.166
=637,465

Amgen's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=199877.025+(406455.284+19163.177
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+10196.848+0+20930.352)
=657,983

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=749589.79-91607.038
=657,983

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$657,983 Mil mean?
Amgen (HKSE:04332) has a Total Liabilities of HK$657,983 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Amgen and its competitors.
Is Amgen's Total Liabilities too high?
Amgen's current Total Liabilities is HK$657,983 Mil. Overall, Amgen has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Amgen's Total Liabilities compare to GILD and PFE?
Amgen's Total Liabilities of HK$657,983 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Amgen and its competitors. Amgen's current Total Liabilities is HK$657,983 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Amgen (HKSE:04332) has a current Total Liabilities of HK$657,983 Mil. The stock's GF Value™ is HK$1,463.66, compared to a current price of HK$1,761.00 — trading 20.3% above its estimated fair value. The current Total Liabilities is HK$657,983 Mil. Amgen's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Amgen (HKSE:04332), the current Total Liabilities is HK$657,983 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (HKSE:04332) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of HK$1,761.00 is trading 20.3% above its estimated GF Value™ of HK$1,463.66.

Key valuation signals for HKSE:04332:

  • Total Liabilities: HK$657,983 Mil
  • GF Value™: HK$1,463.66 vs. price of HK$1,761.00 (20.3% above fair value)
  • GF Score™: 79/100 with 8 warning signs

No single metric tells the full story. See the HKSE:04332 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
79GF Score

Get the complete analysis for HKSE:04332

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1,761.00
Price
HK$1,463.66
GF Value